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Cardiolipin (CL), a mitochondria-specific gly-
cerophospholipid, is required for diverse mito-
chondrial processes and orchestrates the function
of various death-inducing proteins during
apoptosis. Here, we identify a complex of the p53-
regulated protein TRIAP1 (p53CSV) and PRELI
in the mitochondrial intermembrane space (IMS),
which ensures the accumulation of CL in mito-
chondria. TRIAP1/PRELI complexes exert lipid
transfer activity in vitro and supply phosphatidic
acid (PA) for CL synthesis in the inner mem-
brane. Loss of TRIAP1 or PRELI impairs the accu-
mulation of CL, facilitates the release of cytochrome
c, and renders cells vulnerable to apoptosis
upon intrinsic and extrinsic stimulation. Survival of
TRIAP1- and PRELI-deficient cells is conferred by
an excess of exogenously provided phosphatidyl-
glycerol. Our results reveal a p53-dependent cell-
survival pathway and highlight the importance of
the CL content of mitochondrial membranes in
apoptosis.
INTRODUCTION
Apoptosis is a highly regulated genetic program under the con-
trol of intrinsic and extrinsic signaling pathways, which converge
on mitochondria. Signal transduction during programmed cell
death depends on CL, a mitochondria-specific dimeric glycero-
phospholipid that affects apoptotic signaling in various ways
(Schug and Gottlieb, 2009). CL retains cytochrome c at the mito-
chondrial inner membrane, promotes the oligomerization of
BCL2-family members in the outer membrane, and triggers cas-
pase-8 activation and formation of tBid during mitochondrial
amplification of extrinsic apoptotic signals (Gonzalvez et al.,
2008; Osman et al., 2011). Apoptosis is associated with exten-
sive remodeling of cristae membranes and detachment of cyto-
chrome c from CL facilitating its redistribution within the IMS and
release from mitochondria (Iverson and Orrenius, 2004; Scor-
rano et al., 2002).CelApoptotic signaling is regulated at multiple levels by the
sequence-specific transcription factor p53, with more than 100
genes containing p53 binding sites (Riley et al., 2008). However,
the function of many of these genes remained enigmatic. This in-
cludes TP53-regulated inhibitor of apoptosis gene 1 (TRIAP1 or
p53CSV), which contains a p53 binding site within its coding
sequence and is upregulated in multiple myeloma (Felix et al.,
2009; Park and Nakamura, 2005). TRIAP1 has been shown to
inhibit apoptosis potentially by interacting with cytoplasmic
Hsp70 and Apaf1 (Park and Nakamura, 2005) and recently was
identified as a repressor of p21 (Andrysik et al., 2013), but the
precise mechanism of TRIAP1 function remained unaddressed.
TRIAP1 attracted our attention because it is homologous to
yeast Mdm35, a regulator of mitochondrial phospholipid biogen-
esis (Potting et al., 2010; Tamura et al., 2010). Here, we identify
TRIAP1 and PRELI as subunits of an intramitochondrial lipid
transfer complex promoting CL accumulation and linking p53-
mediated cell survival to mitochondrial CL.
RESULTS
TRIAP1 Modulates the Mitochondrial Pathway of
Apoptosis
We depleted HeLa cells of TRIAP1 by siRNA-mediated downre-
gulation and assessed the susceptibility of the cells toward acti-
nomycin D (ActD)-induced apoptosis (Figure 1A and see
Figure S1 online). In agreement with previous findings in UV-
treated cells (Park and Nakamura, 2005), we observed an
increased rate of apoptosis specifically in TRIAP1-depleted
cells, as monitored by the accumulation of cleaved poly ADP-
ribose polymerase (cPARP; Figure 1A; see Figure 4E for
quantification). Transient expression of TRIAP1HA harboring a
C-terminal HA-tag partially prevented the formation of cPARP
(Figure 1A). Moreover, we treated TRIAP1-depleted cells with
TNF-a/CHX to induce apoptosis extrinsically. cPARP accumu-
lated faster in cells depleted of TRIAP1 than in control cells, sug-
gesting a function for TRIAP1 in both intrinsic and extrinsic path-
ways of apoptosis (Figure 1B; see Figure 4H for quantification).
These findings prompted us to examine a potential role of
mitochondria in TRIAP1-dependent apoptosis. Upon ActD treat-
ment, cytochrome c accumulated in the cytosol in a significantly
increased number of TRIAP1-depleted cells (Figure 1C; see Fig-
ure 4B for quantification), indicating that the loss of TRIAP1 facil-
itates the release of cytochrome c from mitochondria.l Metabolism 18, 287–295, August 6, 2013 ª2013 Elsevier Inc. 287
Figure 1. Mitochondrial TRIAP1 Protects against Apoptosis
(A) Increased susceptibility of TRIAP1-deficient cells toward actinomycin D (ActD)-induced apoptosis. HeLa cells were transfected with scrambled (SCR) or
TRIAP1-specific siRNAs and either a control plasmid (EV) or a plasmid that contains siRNA-resistant TRIAP1 encoding HA-tagged TRIAP1 (TRIAP1HA). After
induction of apoptosis with ActD (0.05 mM), cells were harvested at the indicated time points and analyzed by SDS-PAGE and immunoblotting. See Figure 4E for
quantification. PRELI levels are decreased upon downregulation of TRIAP1, which is required for PRELI stability (see Figure 2). cPARP, cleaved PARP; HA, HA-
specific antibodies.
(B) Increased susceptibility of TRIAP1-deficient cells toward apoptosis induced with TNF-a (0.2 ng/ml)/CHX (1 mg/ml). See Figure 4H for quantification.
(legend continued on next page)
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interacting with cytosolic Hsp70 and Apaf1 (Park and Nakamura,
2005), its cellular localization remained to be clarified. Confocal
immunofluorescence microscopy following ectopic expression
of TRIAP1HA in HeLa cells showed a reticulate distribution of
TRIAP1HA and colocalization with cytochrome c, suggesting a
mitochondrial localization of TRIAP1 (Figure 1D). Consistently,
TRIAP1HA was present in mitochondria purified from these cells
(Figure 1E). To determine the submitochondrial localization of
TRIAP1, we performed protease protection experiments upon
fractionation of mitochondria. TRIAP1HA remained stable against
externally added protease and was only degraded under hypo-
tonic conditions, which result in the osmotic disruption of the
outer membrane (Figure 1E). We conclude from these experi-
ments that TRIAP1 is localized in the mitochondrial IMS.
TRIAP1 Assembles with PRELI in the IMS
Proteins homologous to TRIAP1 are present in all eukaryotic
kingdoms (Figure 2A). The yeast member of this family,
Mdm35, binds Ups1, which is homologous to PRELI (protein of
relevant evolutionary and lymphoid interest) that we found to
localize to the IMS as well (Figure 1E) (Dee and Moffat, 2005;
Fox et al., 2004). In agreement with previous findings (McKeller
et al., 2010), downregulation of PRELI increased the susceptibil-
ity of HeLa cells toward apoptosis upon treatment with ActD or
TNF-a/CHX, as indicated by augmented PARP cleavage and
facilitated cytochrome c release from mitochondria (Figures
2B–2D; see Figure 4 for quantification).
PRELI was rapidly degraded upon induction of apoptosis (Fig-
ures 2B and 2C). Expression of a catalytically inactive variant of
the i-AAA protease YME1L, harboring a mutation in the Walker B
motif of the AAA ATPase domain (YME1LE381Q), led to the accu-
mulation of PRELI (Figure 2E). Similarly, siRNA-mediated down-
regulation of YME1L stabilized PRELI, indicating proteolysis of
PRELI by YME1L (Figure 2F). Notably, the steady-state level of
PRELI was dependent on TRIAP1. PRELI accumulated upon
overexpression of TRIAP1HA in YME1L-depeleted mitochondria
(Figure 2F), while it was present at reduced levels inmitochondria
lacking TRIAP1 (Figure 2G). Thus, it appears that TRIAP1 pro-
tects PRELI against YME1L-mediated proteolysis, suggesting
a physical interaction between TRIAP1 and PRELI.
To test this hypothesis, we transiently expressed TRIAP1HA in
cells depleted of YME1L and performed coimmunoprecipitation
experiments using HA-specific antibodies. PRELI was specif-
ically precipitated with TRIAP1HA (Figure 2H). Furthermore,
upon size exclusion chromatography of mitochondrial extracts,
endogenous TRIAP1 and PRELI coeluted from the column in
fractions corresponding to amolecular weight of100 kDa, indi-
cating complex formation of both proteins (Figure 2I). Consis-
tently, when extracts of PRELI-depleted mitochondria were
analyzed, TRIAP1 eluted in low-molecular-weight fractions,(C) Increased cytochrome c release upon downregulation of TRIAP1. Apoptosis
[OME]-FMK). After 6 hr, cells were stained with mitotracker, DAPI, and cytochro
(D) TRIAP1HA is localized in mitochondria. HeLa cells transiently expressing TR
Scale bar, 10 mm.
(E) TRIAP1HA localizes to the IMS. Mitochondria harboring TRIAP1HA were subjec
solubilized with Triton X-100 (TX-100) as indicated.
See also Figure S1.
Cellikely representing unassembled TRIAP1. We conclude from
these experiments that TRIAP1 and PRELI form a complex in
the intermembrane space (IMS) of mitochondria.
TRIAP1/PRELI Complexes Ensure the Accumulation of
CL in Mitochondrial Membranes
How do TRIAP1/PRELI complexes affect the progression of
apoptosis? PRELI had been proposed to modulate apoptosis
affecting mitochondrial morphology by interaction with the
dynamin-like GTPase OPA1 (McKeller et al., 2010). However,
we detected tubular mitochondria in the majority of cells lacking
TRIAP1 or PRELI and observed mitochondrial fragmentation
in only a minority of PRELI-deficient cells (Figures 3A and 3B).
On the other hand, the basal oxygen consumption, as well
as electron transfer capacity, was significantly decreased in
PRELI-depleted cells (Figure 3C). Moreover, fewer respiratory
supercomplexes containing cI, cIII, and cIV accumulated in
TRIAP1-depleted and, more drastically, PRELI-depleted mito-
chondria (Figure 3D).
Since both the stability of respiratory supercomplexes and the
apoptotic resistance of cells depend on CL (Osman et al., 2011),
we assessed CL levels in TRIAP1- and PRELI-deficient mito-
chondria by mass spectrometry (MS). The loss of TRIAP1
resulted in a statistically significant reduction of mitochondrial
CL but had only minor effects on other phospholipids, including
phosphatidylcholine (PC), phosphatidylethanolamine (PE),
phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidyl-
glycerol (PG), or phosphatidic acid (PA) (Figure 3E). CL levels
were more drastically decreased in PRELI-depleted mitochon-
dria (Figure 3F). Moreover, PG, which serves as a precursor lipid
for the synthesis of CL, was decreased in these cells, while PE
levels were slightly increased and may partially compensate for
the loss of CL (Figure 3F). Thus, the loss of PRELI, and to
some extent of TRIAP1, causes significant dysregulation of the
lipid composition of mitochondrial membranes, with the most
prominent effect on the accumulation of CL.
TRIAP1/PRELI Complexes Facilitate the Transport of PA
In Vitro
CL is synthesized along an enzymatic cascade in the IM (Chicco
and Sparagna, 2007; Claypool and Koehler, 2012; Houtkooper
and Vaz, 2008). The observation of reduced CL levels in TRIAP1-
and PRELI-deficient mitochondria raised the intriguing possibil-
ity that TRIAP1/PRELI complexes act as lipid transfer proteins in
the IMS of human mitochondria, as was recently demonstrated
for Mdm35/Ups1 complexes in yeast (Connerth et al., 2012).
We therefore purified TRIAP1/PRELI complexes after coexpres-
sion of both proteins from E. coli and assessed their ability to
transport phospholipids between liposomes in vitro (Figure S2B).
TRIAP1/PRELI complexes facilitated the transfer of PA, a CL pre-
cursor phospholipid, in a concentration-dependent manner,was induced with ActD (0.2 mM) in the presence of caspase inhibitor (Z-VAD
me c-specific antibodies. Scale bar, 12 mm.
IAP1HA were immunostained with HA- and cytochrome c-specific antibodies.
ted to osmotic swelling (SW) or Proteinase K treatment (PK; 50 mg/ml) or were
l Metabolism 18, 287–295, August 6, 2013 ª2013 Elsevier Inc. 289
Figure 2. TRIAP1 Assembles with PRELI in the Intermembrane Space of Mitochondria
(A) Multiple sequence alignment of Saccharomyces cerevisiae (S.c.) Mdm35, Homo sapiens (H.s.) TRIAP1, and homologs from Mus musculus (M.m.) and Ara-
bidopsis thaliana (A.t.). Amino acids conserved across species are highlighted in black, similar amino acids are highlighted in dark gray, and light gray highlighting
indicates conservation in at least two species. Red arrows point to the twin Cx9C motif.
(B and C) Increased susceptibility of PRELI-deficient cells toward apoptosis induced with ActD (0.05 mM) (B) or TNF-a (0.2 ng/ml)/CHX (1 mg/ml) (C). See Figures
4E and 4H for quantification.
(legend continued on next page)
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Intramitochondrial Lipid Transfer and Apoptosiswhile PI, PS, PG, and CL were not transported (Figure 3G). We
observed some transport of CDP-diacylglycerol (CDP-DAG) by
TRIAP1/PRELI complexes, albeit with drastically lower efficiency
(Figure 3G). To substantiate these findings, we devised a fluo-
rescence-based lipid transfer assay using NBD-PA (Figure 3H).
Donor liposomes containing NBD-PA and rhodamine-PE that
quenches NBD fluorescence were incubated with acceptor
liposomes lacking fluorescent lipids. Dequenching of NBD
fluorescence allows monitoring of the transfer of NBD-PA.
TRIAP1/PRELI complexes accelerated dequenching of NBD-
PA in a concentration-dependent manner (Figure 3I). Only trace
amounts of rhodamine fluorescence were detected in isolated
acceptor liposomes after the reaction excluding transfer of
rhodamine-PE or liposome fusion (data not shown).
We conclude that TRIAP1/PRELI complexes mediate the
transfer of PA between liposomes in vitro. Therefore, the
reduced CL levels in TRIAP1- or PRELI-deficient mitochondria
likely result from an impaired PA transport limiting CL synthesis.
PG Restores Apoptotic Resistance of Cells Lacking
TRIAP1 or PRELI
To demonstrate directly that reduced CL levels cause the
decreased apoptotic resistance of cells lacking either TRIAP1
or PRELI, we supplied these cells with excess PG to artificially
restore CL-dependent functions in mitochondria. PG can at least
partially substitute for CL functions, e.g., in binding cytochrome
c (Chang et al., 1998; Ryto¨maa and Kinnunen, 1994). After incu-
bation of cells with NBD-PG and a lipid-based transfection
reagent, cellular lipid extracts were analyzed by thin-layer chro-
matography (TLC). Fluorescent signals indicated uptake of NBD-
PG by the cells (Figure 4A). We observed multiple fluorescent
bands suggesting that NBD-PG is metabolized and contributes
to the biogenesis of distinct lipid species. Although prominent
species remain to be identified, we observed comigration of fluo-
rescent signals with CL, which were slightly reduced in extracts
from cells transfected with cardiolipin synthase (CRLS1)-specific
siRNAs, therefore likely representing NBD-CL (Figure 4A; see
Figure S3A for quantification). Notably, although NBD-PG was
taken up with similar efficiency, synthesis of NBD-CL was signif-
icantly enhanced in PRELI-depleted cells (Figure 4A). Thus,
externally added PG can be taken up by the cells and reaches
the mitochondrial inner membrane where it is, at least to a minor
extent, converted into CL.
Next, we assessed the apoptotic resistance of TRIAP1- and
PRELI-deficient cells that had received PG treatment. PG accu-
mulated in lipid extracts of these cells, while CL levels remained
largely unaffected (Figure S3B). When incubated with ActD, we
observed a marked retention of mitochondrial cytochrome c in
both TRIAP1- and PRELI-deficient cells containing excess PG,(D) Loss of PRELI facilitates cytochrome c release from mitochondria upon ActD
(E) Accumulation of PRELI upon tetracycline-induced, stable expression of prote
(F) Mitochondrial accumulation of PRELI upon downregulation of YME1L in HeLa
was higher in YME1L-depleted cells as monitored by cotransfection of a plasmid
(G) Reduced steady-state level of PRELI in TRIAP1-deficient mitochondria.
(H) PRELI assembles with TRIAP1HA. Mitochondria depleted of YME1L and harb
ubilized with digitonin, and coimmunoprecipitation was performed using HA-spe
(5%), and the eluate (E; 100%).
(I) Mitochondria from cells treated with indicated siRNAs were solubilized with do
only detected in the input fraction upon long exposure of the gel.
Celbut not in control cells (Figure 4B and Figure S3C). Moreover,
PARP cleavage was significantly reduced in these cells (Figures
4C–4E). Similarly, addition of excess PG protected cells lacking
TRIAP1 or PRELI against TNF-a/CHX-induced apoptosis (Fig-
ures 4F–4H) but did not affect the formation of cPARP in ActD-
or TNF-a/CHX-treated control cells (Figures S3D and S3E).
These experiments demonstrate that excess PG partially
restores the apoptotic resistance of TRIAP1- and PRELI-defi-
cient cells.
DISCUSSION
TRIAP1 and PRELI were previously shown to be required for
apoptotic resistance (McKeller et al., 2010; Park and Nakamura,
2005), but the molecular role of either protein remained
obscure. We demonstrate here that TRIAP1 and PRELI
assemble into a lipid transfer complex in mitochondria, which
mediates the transport of PA across the IMS and provides PA
for CL synthesis in the inner membrane. Decreased CL levels
in the absence of TRIAP1 or PRELI facilitate the release of
cytochrome c from mitochondria, rendering cells vulnerable to
apoptosis.
Purified TRIAP1/PRELI complexes transfer PA between lipo-
somes in vitro, demonstrating lipid transfer activity. They exert
a high specificity for PA, although we observed TRIAP1/PRELI-
dependent transport of CDP-DAG with low efficiency. The
assembled TRIAP1/PRELI complex likely represents the func-
tionally active structure not only in vitro but also in vivo, as we
observed reduced steady-state levels and proteolysis of PRELI
in TRIAP1-depleted cells. Therefore, the loss of the assembled
complex likely causes deficiencies in the absence of either
PRELI or TRIAP1. The function of TRIAP1/PRELI complexes as
PA transfer proteins is evolutionary conserved from yeast to
man (Connerth et al., 2012). Notably, Mdm35 assembles with
different members of the Ups1-family in yeast, affecting the
accumulation of other phospholipids like PE in mitochondrial
membranes (Potting et al., 2010; Tamura et al., 2010). Although
the majority of TRIAP1 appears to assemble with PRELI, the
functional conservation of TRIAP1/PRELI complexes opens up
the possibility that depending on cell type or physiological con-
ditions TRIAP1 also assembles with human homologs of PRELI
into independent lipid transfer complexes.
We observed only a partial reduction in the CL levels in
TRIAP1- and PRELI-deficient mitochondria, which might be
explained by a limited knockdown efficiency in these experi-
ments. Alternatively, other pathways may exist, which provide
PA to the CL biosynthetic cascade if PA cannot be transported
across the IMS. Mitochondria harbor the acylglycerol kinase
AGK, which is mutated in Sengers syndrome (Mayr et al.,(0.2 mM) treatment. See Figure 1C. Scale bar, 12 mm.
olytically inactive YME1LE381Q in HEK293 cells.
cells, transiently expressing TRIAP1HA when indicated. Transfection efficiency
carrying EGFP (data not shown). HA, HA-specific antibodies.
oring either a control plasmid (EV) or a plasmid encoding TRIAP1HA were sol-
cific antibodies. Total (T), pellet (P), supernatant (S), flowthrough (Ft) fractions
decylmaltoside and fractionated by size exclusion chromatography. TRIAP1 is
l Metabolism 18, 287–295, August 6, 2013 ª2013 Elsevier Inc. 291
(legend on next page)
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phosphorylation of diacylglycerol or monoacylglycerol to PA or
lyso-PA, respectively, and therefore has been proposed to
contribute to CL synthesis (Bektas et al., 2005; Mayr et al.,
2012). Moreover, genetic evidence in yeast points to alternative
CL synthesis routes (Connerth et al., 2012; Tamura et al., 2013).
While components involved in this pathway remain to be identi-
fied, our experiments provide evidence for the existence of an
additional CL synthesis pathway in human mitochondria. CL
synthesis from exogenously added PG was strongly increased
upon downregulation of PRELI, suggesting that the impaired
transport of PA across the IMS stimulates CL synthesis from
PG along another pathway.
CL is critical for a variety of cellular processes and essential
for embryonic development in mice (Zhang et al., 2011). Loss
of CL, an altered acyl chain composition of CL, and/or CL
peroxidation has been linked to aging and a variety of patho-
physiological conditions, including ischemia, heart failure, and
cardiomyopathies (Chicco and Sparagna, 2007; Claypool and
Koehler, 2012; Houtkooper and Vaz, 2008). While the general
importance of CL and CL peroxidation for apoptotic signaling
has been recognized (Kagan et al., 2005; Schug and Gottlieb,
2009), anti- and proapoptotic effects have been observed
upon downregulation of the CL synthase CRLS1 (Choi et al.,
2007; Huang et al., 2008). Our results establish the protective
effect of CL against the release of cytochrome c and apo-
ptosis. Silencing of TRIAP1 or PRELI impairs the accumulation
of CL and increases the susceptibility of these cells to
apoptosis. The restoration of the apoptotic resistance of these
cells by excess PG demonstrates a direct link between CL
dysregulation and apoptosis. Thus, similar to CL peroxidation,
the loss of CL facilitates cytochrome c release and apoptotic
signaling.
The central role of TRIAP1withinmitochondrial CLmetabolism
and apoptotic signaling sheds new light on the regulation of
TRIAP1 expression by p53. TRIAP1 allows cell-cycle progres-
sion (Andrysik et al., 2013) and is upregulated in multiple
myeloma (Felix et al., 2009), and low genotoxic stress causes
p53-mediated expression of TRIAP1 and increased cell survival
(Park and Nakamura, 2005). On the other hand, PRELI has been
identified as a regulator of lymphocytic apoptosis and differenti-
ation (McKeller et al., 2010; Tahvanainen et al., 2009). Our results
explain these observations by the role of TRIAP1/PRELI com-
plexes in intramitochondrial PA trafficking and CL synthesis.Figure 3. The Accumulation of CL in Mitochondria Depends on TRIAP
(A) Mitochondrial morphology in TRIAP1- and PRELI-deficient cells. Cells tran
c-specific antibodies. Scale bar, 10 mm.
(B) Statistical evaluation of mitochondrial morphologies. More than 200 cells we
(C) Oxygen consumption rates of intact cells transfected with indicated siRNAs.
transfer system capacity (ETS) are shown. Inhibition of electron flow through comp
(ROX) is unaffected by PRELI downregulation. n = 3. Error bars represent SD va
(D) Impaired formation of respiratory supercomplexes in PRELI-deficient mitochon
siRNAs, solubilized with 1.5% digitonin (6 g/g protein) and analyzed by blue na
complexes (c) I, III, and IV. SC, respiratory supercomplexes (Acı´n-Pe´rez et al., 20
(E and F) Reduced CL in TRIAP1- (E) and PRELI-deficient (F) mitochondria. M
assessment of the purity of mitochondria); lipids were extracted and quantified b
(G) Phospholipid transfer by TRIAP1/PRELI complexes in vitro.
(H) Schematic representation of the lipid transfer assay using NBD-PA.
(I) Transport of NBD-PA by TRIAP1/PRELI complexes.
See also Figure S2.
CelEXPERIMENTAL PROCEDURES
siRNA Experiments and Transfections
siRNA-mediated downregulation was performed using specific or scrambled
siRNAs (SCR) and Lipofectamine RNAiMax (Life Technologies) according to
themanufacturer’s instructions.Cellsweregrown for2days,and, if not indicated
otherwise, media was replaced followed by 12 hr incubation prior to harvesting.
Downregulation efficiency was assessed by immunoblotting or qRT-PCR.
For expression of siRNA-resistant TRIAP1HA, human TRIAP1 cDNA was
cloned into pcDNA5FRT/TO (Invitrogen). Silent mutations were introduced into
thesiRNAtarget sequence,and theHA-tagcodingsequencewas insertedbefore
the stop codon by PCR. Transfections were performed using the GeneJuice
transfection reagent (Novagen) according to the manufacturer’s instructions.
Analysis of Apoptotic Resistance
Adherent cells were washed in PBS before adding fresh media supplemented
with ActD or TNF-a/CHX as indicated. Cells were harvested at indicated time
points, lysed, and analyzed by SDS-PAGE and immunoblotting as indicated.
Increase of Cellular PG Levels
Cells were seeded in standard growth media and transfected essentially
according to manufacturer’s instructions using PG-supplemented Optimem
media (Optimem [Life Technologies] supplemented with 0.15 mM PG- or
NBD-PG). PG-supplemented Optimem media was sonicated prior to use in
transfections. After 2.5 days, adherent cells were washed in PBS, and fresh
media was added. For whole-cell lipid analyses, cells were harvested and
lipids were analyzed by MS or by TLC.
Monitoring Phospholipid Transfer In Vitro
MS analysis of lipids and lipid transfer assays were performed essentially as
described (Connerth et al., 2012). Donor liposomes (25 mM), whose lipid
composition resembled the OM (PC/PE/PI/CL/PA/PG/PS/CDP-DAG/NBD-
PE/N-lactosyl-PE = 40%/9.6%/5%/5%/5%/5%/5%/%5/0.4/10%) and
acceptor liposomes (100 mM; PC/PE/Rhod-PE = 50%/49.9%/0.1%) were
incubated with indicated concentrations of TRIAP1/PRELI complexes.
Acceptor membranes were isolated by flotation, and phospholipids were
quantified by MS. To monitor the kinetics of the transfer reaction, donor lipo-
somes (12.5 mM; PC/PE/18:1–12:0 NBD-PA/Rhod-PE = 50%/40%/8%/2%)
and acceptor liposomes (50 mM; PC/PE/PA = 50%/40%/10%) were incubated
with TRIAP1/PRELI complexes, and NBD fluorescence was monitored.
Miscellaneous
Further experimental procedures can be found in the Supplemental
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
online at http://dx.doi.org/10.1016/j.cmet.2013.07.008.1 and PRELI
sfected with the indicated siRNAs were stained with DAPI and cytochrome
re analyzed. n = 3. Error bars represent SD values. *p < 0.05.
The basal rate, the complex V inhibited (Leak) rate, and the maximal electron
lex I and III demonstrates that nonmitochondrial residual oxygen consumption
lues. *p < 0.05.
dria. Mitochondria were isolated fromHeLa cells transfected with the indicated
tive gel electrophoresis and immunoblotting with antibodies directed against
08). Note that lower signals in the cIII panel represent residual cIV signals.
itochondria were purified from siRNA-treated HeLa cells (see Figure S2A for
y MS. n = 3. Error bars represent SD values. *p < 0.05; **p < 0.01.
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Figure 4. Excess PG Restores the Apoptotic
Resistance of TRIAP1- and PRELI-Deficient
Cells
(A) Cellular uptake of exogenously supplied NBD-PG
by HeLa cells. Cellular phospholipids were se-
parated by TLC and analyzed by fluorescence
scanning (left panel) prior to staining with CuSO4
(right panel). Standard phospholipids allowed the
identification of lipid spots. Fluorescent bands are
specific for NBD, as no signals were detected in the
absence of NBD-PG (data not shown). s.a., sample
application.
(B) Excess PG suppresses cytochrome c release
upon silencing of TRIAP1 or PRELI. HeLa cells were
transfected with siRNAs and incubated with excess
PG and ActD (0.2 mM) in the presence of caspase
inhibitor (Z-VAD[OME]-FMK); >200 cells; n = 3. Error
bars represent SD values. **p < 0.01; ***p < 0.001.
(C–E) Excess PG suppresses ActD-induced cleav-
age of PARP in TRIAP1- or PRELI-deficient cells.
HeLa cells were transfected with siRNAs and incu-
bated with excess PG as indicated. The accumula-
tion of cPARP after ActD treatment (0.05 mM) was
assessed by SDS-PAGE and immunoblotting (C and
D) and quantified by infrared laser scanning (E). n = 3.
Error bars represent SD values. *p < 0.05; ***p <
0.001.
(F–H) Excess PG suppresses TNF-a/CHX-depen-
dent cleavage of PARP. HeLa cells were transfected
with siRNAs and incubated with excess PG as indi-
cated. PARP cleavage after TNF-a (0.2 ng/ml)/CHX
(1 mg/ml) treatment was assessed (F and G) and
quantified (H) as above. n = 3. Error bars represent
SD values. *p < 0.05; **p < 0.01.
See also Figure S3.
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